Report on the General Shareholders’ Meeting
Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), held an Ordinary and Extraordinary General Shareholders’ Meeting on second call on 4 April 2019 at the Group’s registered office, chaired by Stéphane Le Roux, which approved all the resolutions submitted except the tenth resolution, which was rejected at the Board of Directors’ suggestion.
Next communication: 2018 annual results – 29 April 2019
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015). ISIN: FR0011398874 - ALSPW
Contacts:
| Spineway Shareholder-services line Available Tuesday through Thursday (10 a.m. – 12 p.m.) +33 (0)811 045 555 | Aelium Finance et Communication Investor relations Solène Kennis spineway@aelium.fr |
Attachment
